Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway

Cisplatin (DDP) represents one of the common drugs used for esophageal squamous cell carcinoma (ESCC), but side effects associated with DDP and drug resistance lead to the failure of treatment. This study aimed to understand whether tanshinone IIA (tan IIA) and DDP could generate a synergistic antit...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Xiaozhong, Gao, Ying, Liu, Jiahui, Tao, Lanting, Wang, Dongmei, Xie, Dan, Mo, Suilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511800/
https://www.ncbi.nlm.nih.gov/pubmed/33014864
http://dx.doi.org/10.3389/fonc.2020.01756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511800/
https://www.ncbi.nlm.nih.gov/pubmed/33014864
http://dx.doi.org/10.3389/fonc.2020.01756

Ejemplares similares